Launch FDA-Regulated Products With Confidence — Without Wasting Years or Capital
Kandih Bioscience helps founders navigate FDA registration, toxicology strategy, preclinical planning, and regulatory submissions before costly mistakes delay approvals, funding, or commercialization.
Safety risk found late is the most expensive risk of all.
Toxicology sits early in the development timeline — but its consequences compound across years and funding rounds. Discover a gap late, and the bill arrives as delay, stranded value, or litigation. Strong preclinical regulatory strategy turns that timeline from a liability into a roadmap.
Gaps surface too late
Toxicology gaps show up only at IND, when the program is already committed.
Profile misses the market
The safety profile doesn't match market and payer expectations at launch.
Signals emerge post-market
Safety signals appear after approval, when remediation is most costly.
The core problem: investors and founders need an early system for translating toxicology risk into funding and milestone decisions — not a compliance report that arrives after the capital is already spent.
From compliance cost center to decision engine.
We turn toxicology into a decision engine for clinical and capital strategy — four moves that connect safety risk directly to your pathway, your spend, and your next milestone.
De-Risk Early
FDA pathway consulting that maps the regulatory route, the key questions, and the decision points — in 4–6 weeks, before spend is locked in.
Design Only What Matters
A focused GLP toxicology strategy: prioritize the studies that actually change IND, 510(k) clearance, partnering, or financing decisions.
Build a Defensible Base
Integrate literature, precedent, standards, and comparator logic into an IND-enabling toxicology risk register investors and regulators can follow.
Decision-Ready Outputs
A regulatory roadmap, study strategy, and toxicology narrative aligned to FDA expectations.
How Kandih Supports Your FDA Journey
Discovery & Product Review
Understand your product, intended claims, target market, and regulatory risks.
Regulatory Pathway Assessment
Identify the fastest viable FDA pathway and required evidence strategy.
Testing & Toxicology Strategy
Design focused safety and preclinical plans aligned with FDA expectations.
Submission Readiness
Prepare regulatory documentation and next-step execution plans for FDA engagement.
One expert on your program. A full network behind it.
Every program is led by a board-certified toxicologist (DABT) with 20+ years across AstraZeneca, NAMSA, and founder-led advisory work. When lab studies or specialist review are needed, a vetted network of GLP labs, CRO partners, and senior reviewers delivers on your timeline — so capacity never becomes a bottleneck.
Principal-Led, Senior-Owned
A board-certified principal owns your strategy end to end — no junior handoffs — so the judgment you buy is the judgment you get.
Vetted Delivery Network
GLP labs, CRO partners, and specialist reviewers, coordinated under one accountable strategy — so capacity and turnaround never bottleneck your program.
Cross-Modality Fluency
Across drugs, devices, biologics, and combinations — where risk assumptions most often break down.
Speed That Protects Runway
Actionable direction in 4–6 weeks, before teams commit months of spend to the wrong evidence plan.
A track record across modalities and borders.
Select engagements across drugs, devices, and biologics — domestic and international.
Federal Research Program
IND-enabling toxicology strategy and GLP study design for translational advancement.
Early-Stage Cell Therapy Company
Pre-IND strategy, safety framing, and translational planning under high uncertainty.
Global Device & Biopharma Companies
510(k) readiness and medical device biocompatibility planning alongside IND/BLA strategy across diverse evidence packages.
Orthopedic Device Manufacturer
Risk assessment and medical device biocompatibility planning for spinal-implant safety and EU MDR alignment.
International Biopharma (Australia)
GLP study oversight, IND/BLA readiness, and FDA Type C meeting support.
U.S. Specialty Pharma Company
Regulatory pathway optimization, resubmission strategy, and targeted safety testing.
Turning pathway ambiguity into a faster FDA strategy.
Converting regulatory ambiguity into a faster, lower-waste FDA strategy.
The program faced a clinical hold with an unclear regulatory pathway — and pressure to test broadly and re-manufacture.
Rebuilt a targeted safety-testing plan and defined a practical regulatory roadmap focused on evidence relevant to clearance — so the team avoided broad testing and re-manufacturing.
- Eliminated unnecessary testing
- Avoided costly rework
- Positioned the program for FDA clearance
Facing a similar pathway question? Get a focused review of your program's safety risk.
Request a Toxicology Risk Assessment →De-risk before you deploy capital.
Kandih gives founders and investors an early toxicology intelligence layer — before development spend is committed.
4–6 Week Regulatory Pathway + Risk Register Sprint
- Regulatory pathway mapped with key questions and decision points
- Prioritized study strategy tied to IND / 510(k) / financing milestones
- Investor-ready risk register and toxicology narrative